Kura Oncology Inc (KURA)
20.63
+0.04
(+0.19%)
USD |
NASDAQ |
May 03, 16:00
20.63
0.00 (0.00%)
After-Hours: 20:00
Kura Oncology Enterprise Value: 1.054B for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | 1.054B |
| May 02, 2024 | 1.051B |
| May 01, 2024 | 1.027B |
| April 30, 2024 | 976.92M |
| April 29, 2024 | 1.010B |
| April 26, 2024 | 979.20M |
| April 25, 2024 | 929.69M |
| April 24, 2024 | 910.64M |
| April 23, 2024 | 909.12M |
| April 22, 2024 | 867.98M |
| April 19, 2024 | 817.70M |
| April 18, 2024 | 829.13M |
| April 17, 2024 | 852.74M |
| April 16, 2024 | 898.45M |
| April 15, 2024 | 930.45M |
| April 12, 2024 | 966.25M |
| April 11, 2024 | 1.036B |
| April 10, 2024 | 998.25M |
| April 09, 2024 | 1.058B |
| April 08, 2024 | 1.038B |
| April 05, 2024 | 1.033B |
| April 04, 2024 | 1.033B |
| April 03, 2024 | 1.032B |
| April 02, 2024 | 1.045B |
| April 01, 2024 | 1.145B |
| Date | Value |
|---|---|
| March 28, 2024 | 1.209B |
| March 27, 2024 | 1.197B |
| March 26, 2024 | 1.140B |
| March 25, 2024 | 1.183B |
| March 22, 2024 | 1.215B |
| March 21, 2024 | 1.211B |
| March 20, 2024 | 1.256B |
| March 19, 2024 | 1.237B |
| March 18, 2024 | 1.187B |
| March 15, 2024 | 1.286B |
| March 14, 2024 | 1.259B |
| March 13, 2024 | 1.324B |
| March 12, 2024 | 1.284B |
| March 11, 2024 | 1.323B |
| March 08, 2024 | 1.377B |
| March 07, 2024 | 1.280B |
| March 06, 2024 | 1.314B |
| March 05, 2024 | 1.187B |
| March 04, 2024 | 1.208B |
| March 01, 2024 | 1.229B |
| February 29, 2024 | 1.190B |
| February 28, 2024 | 1.213B |
| February 27, 2024 | 1.242B |
| February 26, 2024 | 1.164B |
| February 23, 2024 | 1.127B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
63.62M
Minimum
Mar 18 2020
2.430B
Maximum
Dec 11 2020
671.97M
Average
554.06M
Median
Nov 22 2021
Enterprise Value Benchmarks
| AIM ImmunoTech Inc | 7.819M |
| Perspective Therapeutics Inc | 1.055B |
| Protalix BioTherapeutics Inc | 58.97M |
| Electromed Inc | 148.76M |
| Armata Pharmaceuticals Inc | 158.79M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -49.52M |
| Total Expenses (Quarterly) | 54.45M |
| EPS Diluted (Quarterly) | -0.59 |
| Earnings Yield | -10.52% |